FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309309135> ?p ?o ?g. }

• W4309309135 endingPage "5610" @default.
• W4309309135 startingPage "5610" @default.
• W4309309135 abstract "Background: Esophageal cancer is still a leading cause of death among all tumors in males, with unsatisfactory responses to novel immunotherapies such as anti-PD-1 agents. Herein, we explored the role of CD155 in esophageal squamous cell cancer (ESCA) and its underlying molecular mechanisms. Methods: Publicly available datasets were used for differential gene expression and immune infiltration analyses, and their correlation with patient survival. A total of 322 ESCA and 161 paracancer samples were collected and evaluated by performing immunohistochemistry and the H score was obtained by performing semiquantitative analysis. In vitro transfection of ESCA cell lines with lentivirus vectors targeting CD155 was performed to knockdown the protein. These cells were analyzed by conducting RNA sequencing, and the effects of CD155 knockdown on cell cycle and apoptosis were verified with flow cytometry and Western blotting. In addition, in vivo experiments using these engineered cell lines were performed to determine the role of CD155 in tumor formation. A small interfering RNA-mediated knockdown of Nectin3 was used to determine whether it phenocopied the profile of CD155 knockdown. Results: CD155 is highly expressed in ESCA tissues and is positively associated with PD1, PDL1, CD4, IL2RA, and S100A9 expression. Furthermore, CD155 knockdown inhibited ESCA cells’ proliferation by impairing the cell cycle and inducing cell apoptosis. Bioinformatics analysis of the gene expression profile of these engineered cells showed that CD155 mainly contributed to the regulation of PI3K/Akt and MAPK signals. The downregulation of Nectin3 expression phenocopied the profile of CD155 knockdown. Discussion: CD155 may cooperate with PD-1/PD-L1 to support ESCA proliferation in ways other than regulating its underlying immune mechanisms. Indeed, CD155 downregulation can impair ESCA cell pro-cancerous behavior via the inhibition of the PI3K/Akt and MAPK signaling pathways. Moreover, Nectin3 may be a ligand of CD155 and participate in the regulation of ESCA cells’ proliferation. Hence, the inhibition of CD155 may enhance the therapeutic effect of anti-PD-1 immunotherapies in ESCA." @default.
• W4309309135 created "2022-11-26" @default.
• W4309309135 creator A5015614663 @default.
• W4309309135 creator A5017417512 @default.
• W4309309135 creator A5020044312 @default.
• W4309309135 creator A5030234564 @default.
• W4309309135 creator A5059292462 @default.
• W4309309135 creator A5063937330 @default.
• W4309309135 creator A5066348800 @default.
• W4309309135 creator A5070812231 @default.
• W4309309135 creator A5074152960 @default.
• W4309309135 creator A5076610905 @default.
• W4309309135 creator A5078507307 @default.
• W4309309135 creator A5079185334 @default.
• W4309309135 creator A5091739094 @default.
• W4309309135 date "2022-11-15" @default.
• W4309309135 modified "2023-10-01" @default.
• W4309309135 title "CD155 Cooperates with PD-1/PD-L1 to Promote Proliferation of Esophageal Squamous Cancer Cells via PI3K/Akt and MAPK Signaling Pathways" @default.
• W4309309135 cites W1841418760 @default.
• W4309309135 cites W1985213868 @default.
• W4309309135 cites W2033107431 @default.
• W4309309135 cites W2039682099 @default.
• W4309309135 cites W2046409157 @default.
• W4309309135 cites W2055765722 @default.
• W4309309135 cites W2081118119 @default.
• W4309309135 cites W2145871366 @default.
• W4309309135 cites W2147643532 @default.
• W4309309135 cites W2272984102 @default.
• W4309309135 cites W2593759473 @default.
• W4309309135 cites W2594294128 @default.
• W4309309135 cites W2606367731 @default.
• W4309309135 cites W2736730167 @default.
• W4309309135 cites W2753155927 @default.
• W4309309135 cites W2798160602 @default.
• W4309309135 cites W2802697853 @default.
• W4309309135 cites W2888408613 @default.
• W4309309135 cites W2913496992 @default.
• W4309309135 cites W2952311237 @default.
• W4309309135 cites W2963473092 @default.
• W4309309135 cites W2982130750 @default.
• W4309309135 cites W3004222930 @default.
• W4309309135 cites W3042410851 @default.
• W4309309135 cites W3081966565 @default.
• W4309309135 cites W3099868841 @default.
• W4309309135 cites W3107527779 @default.
• W4309309135 cites W3127546219 @default.
• W4309309135 cites W3156426224 @default.
• W4309309135 cites W3176248737 @default.
• W4309309135 cites W3189337473 @default.
• W4309309135 cites W3196916802 @default.
• W4309309135 cites W3204424520 @default.
• W4309309135 cites W4206841660 @default.
• W4309309135 cites W4213053670 @default.
• W4309309135 cites W4214729308 @default.
• W4309309135 cites W4223447573 @default.
• W4309309135 cites W4225394054 @default.
• W4309309135 doi "https://doi.org/10.3390/cancers14225610" @default.
• W4309309135 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36428703" @default.
• W4309309135 hasPublicationYear "2022" @default.
• W4309309135 type Work @default.
• W4309309135 citedByCount "3" @default.
• W4309309135 countsByYear W43093091352023 @default.
• W4309309135 crossrefType "journal-article" @default.
• W4309309135 hasAuthorship W4309309135A5015614663 @default.
• W4309309135 hasAuthorship W4309309135A5017417512 @default.
• W4309309135 hasAuthorship W4309309135A5020044312 @default.
• W4309309135 hasAuthorship W4309309135A5030234564 @default.
• W4309309135 hasAuthorship W4309309135A5059292462 @default.
• W4309309135 hasAuthorship W4309309135A5063937330 @default.
• W4309309135 hasAuthorship W4309309135A5066348800 @default.
• W4309309135 hasAuthorship W4309309135A5070812231 @default.
• W4309309135 hasAuthorship W4309309135A5074152960 @default.
• W4309309135 hasAuthorship W4309309135A5076610905 @default.
• W4309309135 hasAuthorship W4309309135A5078507307 @default.
• W4309309135 hasAuthorship W4309309135A5079185334 @default.
• W4309309135 hasAuthorship W4309309135A5091739094 @default.
• W4309309135 hasBestOaLocation W43093091351 @default.
• W4309309135 hasConcept C173396325 @default.
• W4309309135 hasConcept C185592680 @default.
• W4309309135 hasConcept C190283241 @default.
• W4309309135 hasConcept C22615655 @default.
• W4309309135 hasConcept C502942594 @default.
• W4309309135 hasConcept C54009773 @default.
• W4309309135 hasConcept C54355233 @default.
• W4309309135 hasConcept C55493867 @default.
• W4309309135 hasConcept C57074206 @default.
• W4309309135 hasConcept C62112901 @default.
• W4309309135 hasConcept C62478195 @default.
• W4309309135 hasConcept C75217442 @default.
• W4309309135 hasConcept C81885089 @default.
• W4309309135 hasConcept C86554907 @default.
• W4309309135 hasConcept C86803240 @default.
• W4309309135 hasConcept C95444343 @default.
• W4309309135 hasConceptScore W4309309135C173396325 @default.
• W4309309135 hasConceptScore W4309309135C185592680 @default.
• W4309309135 hasConceptScore W4309309135C190283241 @default.
• W4309309135 hasConceptScore W4309309135C22615655 @default.
• W4309309135 hasConceptScore W4309309135C502942594 @default.

• next